Skip to main content
PIRAMAL PHARMA LIMITED logo

PIRAMAL PHARMA LIMITED — Investor Relations & Filings

Ticker · PPLPHARMA ISIN · INE0DK501011 LEI · 3358006D6AL7PZ4U9T51 BSE.NS Manufacturing
Open in API
Filings indexed 367 across all filing types
Latest filing 2024-05-28 Share Issue/Capital Cha…
Country IN India
Listing BSE.NS PPLPHARMA

About PIRAMAL PHARMA LIMITED

https://www.piramalpharma.com/

Piramal Pharma Limited provides a broad range of products and services across the drug lifecycle through three main business segments: Piramal Pharma Solutions, Piramal Critical Care, and Consumer Healthcare. Piramal Pharma Solutions operates as an integrated Contract Development and Manufacturing Organization (CDMO), offering end-to-end services from drug discovery and development to commercial manufacturing of APIs and formulations. Piramal Critical Care focuses on complex hospital generics, holding a significant global market share in inhalation anesthetics, including Sevoflurane and Isoflurane, as well as injectable anesthesia and pain management therapies. The Consumer Healthcare division manages a diverse portfolio of over-the-counter brands such as Saridon, Lacto Calamine, and Tetmosol. The company leverages an extensive global manufacturing network to deliver specialized healthcare solutions worldwide.

Recent filings

Filing Released Lang Actions
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement addressed to stock exchanges (BSE and NSE) regarding the allotment of 2,800,000 equity shares to the company's ESOP Trust under the Employee Stock Option and Incentive Plan 2022. It includes detailed disclosures as per SEBI regulations about the share allotment, share capital changes, and related information. The content focuses on the issuance of new shares and changes in capital structure due to the ESOP allotment. There are no financial statements, earnings data, or management discussion of results. The document is regulatory in nature, specifically about share issuance under an employee stock option plan, which fits the category of Share Issue/Capital Change announcements rather than a full financial report or other categories.
2024-05-28 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short disclosure letter addressed to stock exchanges regarding the successful closure of a US FDA inspection at a manufacturing facility. It references a previous letter and provides an update on regulatory compliance. The document is brief (1446 characters) and serves as an announcement rather than a detailed report or financial statement. It does not contain financial data, audit information, or management discussion. It fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement related to compliance and inspection results, not a full report or financial filing.
2024-05-23 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice dated 17th May 2024, addressed to stock exchanges (BSE and NSE) regarding the schedule of upcoming analyst and institutional investor meetings. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30(6), which pertains to disclosure of material events or information. The content is purely an announcement of scheduled meetings with investors and does not contain any financial data, report, or detailed presentation. The document length is only 1641 characters, indicating it is a brief announcement rather than a full report or presentation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-05-17 English
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 95% confidence The document is a declaration under Regulation 31(4) of SEBI (SAST) Regulations, 2011, stating that the Promoters or Promoter Group have not made any encumbrance on the shares during the financial year 2023-2024. It is addressed to stock exchanges and signed by the Chairman. This is a notification related to shareholding and encumbrance status, which fits the category of Major Shareholding Notification (MRQ). The document is short and does not contain financial statements or detailed reports, so it is not an Annual Report or Interim Report. It is not a report publication announcement or certification. Therefore, the best classification is MRQ with high confidence.
2024-05-16 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the availability of the transcript of a conference call on the audited financial results for the quarter and year ended 31st March 2024. It references the transcript of the conference call held on 13th May 2024 and provides a link to the company's website where the transcript can be accessed. The document itself does not contain the transcript but announces its availability. The document length is short (1409 characters), and it is an announcement rather than the transcript itself. According to the rules, announcements about the availability of conference call transcripts should be classified as Regulatory Filings (RNS) because it is a general regulatory announcement and not the full transcript text.
2024-05-14 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short announcement dated 13th May 2024, informing about the availability of the audio recording of a conference call discussing the audited financial results for the quarter and year ended 31st March 2024. It references a previous letter and provides a link to the recording on the company's website. The document does not contain the transcript itself or detailed financial data, but merely announces the availability of the recording. According to the rules, such announcements about the availability of conference call recordings are classified as Regulatory Filings (RNS) because they are regulatory announcements without substantive financial content or the full transcript.
2024-05-13 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.